The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×7•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

Hims & Hers Stock Jumps as U.S. Moves to Reassess Popular Peptides

Key Facts

1Hims & Hers Health stock jumped following a U.S. move to proceed with a plan to reassess popular peptides.

about 2 months ago

Version History

1 additional source confirmed this story

Version 7about 2 months ago

What changed: The story was updated to include the company's strategic shift toward a global platform, international expansion via acquisitions, and the significance of the Novo Nordisk partnership.

Version 6about 2 months ago

What changed: Updated the story to reflect the stock's continued momentum as a top NYSE performer with sustained 4.5% intraday gains.

Version 5about 2 months ago

What changed: Added analyst commentary regarding the long-term benefits of peptide compounding for the company's growth.

Version 4about 2 months ago

What changed: Updated stock price movement (+8% to $26) and included specific dates for the FDA advisory committee meetings in July.

Version 3about 2 months ago

What changed: The story was updated to highlight the strategic shift in investor focus toward peptides as a replacement for GLP-1 growth, while noting the current lack of robust clinical evidence.

Version 2about 2 months ago

What changed: Updated the story to reflect the significant stock price recovery and new details from Robert F. Kennedy Jr. regarding the removal of peptides from high-risk regulatory categories.

Version 1about 2 months ago

What changed: Bank of America slashed its price target for HIMS due to earnings pressure and sector-wide valuation compression, despite the previous regulatory optimism.

Hims & Hers Health Inc (HIMS) is strengthening its market position as it evolves from a telehealth provider into a scalable, global consumer health platform. This strategic shift is supported by robust revenue growth fueled by international expansion, specifically through the acquisition of Eucalyptus. While markets await FDA decisions regarding the inclusion of peptides on authorized lists, the company's partnership with Novo Nordisk serves as a significant validation of the HIMS platform's capabilities. However, analysts remain cautious regarding persistent regulatory risks associated with compounded obesity treatments. The stock's performance reflects investor confidence in the company's ability to diversify its therapeutic portfolio and achieve sustainable operational profitability. Global expansion remains a primary focus for the firm's future commercial trajectory.